Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection

T. Schacker, A. C. Collier, R. Coombs, J. D. Unadkat, I. Fox, J. Alam, J. P. Wang -, E. Eggert, L. Corey

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

In vitro, recombinant soluble CD4 (rsCD4) attaches to and inactivates human immunodeficiency virus (HIV). To determine if prolonged therapy with high-dose intravenous rsCD4 provides an in vivo benefit, we gave three HIV- 1-infected patients with AIDS, whose isolates were susceptible in vitro to rsCD4, 10 mg/kg of rsCD4 for 4 weeks, 5 mg/kg for 4 weeks, and 1 mg/kg for 2 weeks. Single-dose pharmacokinetic studies performed prior to this showed transient in vivo decreases of HIV-1 plasma viremia in all three subjects. Surrogate markers of HIV activity, clinical status, HIV-1 p24 antigen, plasma HIV-1 titers, and peripheral blood mononuclear cell (PBMC) intracellular titers of virus were measured at entry, and every other week after onset of therapy. All subjects demonstrated rsCD4 concentration-dependent reduction in plasma viremia, with two subjects having complete neutralization of cell- free virus. The third subject's isolate was relatively resistant to the in vivo effects of rsCD4 and only partial reduction in plasma virus titers was obtained, even at the highest dose of 10 mg/kg. There was no change in the PBMC intracellular viral titer or surrogate markers of HIV-1 activity (including CD4 cell count and β2-microglobulin). There was subjective improvement in clinical symptoms, and all subjects gained weight with the highest doses of rsCD4. rsCD4 exhibited linear pharmacokinetics over the dose range studied. We conclude that high-dose intravenous rsCD4 can be safely given for up to 10 weeks and that it has a stable pharmacokinetic profile. Subjects with uniquely susceptible isolates show a consistent, dose-dependent reduction of infectious HIV-1 titer for up to 8 hours. However, two or three times per day dosing may be required to demonstrate a prolonged effect on HIV-1 replication. It appears that sustained high levels of rsCD4 are safe and offer the potential of achieving significant antiviral effects.

Original languageEnglish (US)
Pages (from-to)145-152
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume9
Issue number2
StatePublished - 1995

Keywords

  • HIV
  • IC
  • IC
  • Pharmacokinetics
  • Phase I study
  • rsCD4
  • Viremia

Fingerprint Dive into the research topics of 'Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection'. Together they form a unique fingerprint.

Cite this